1. Curcumin analogue C66 attenuates obesity-induced renal injury by inhibiting chronic inflammation.
- Author
-
Ye L, Hu X, Hu X, Yin S, Chen J, He H, Hong S, Yang B, Singh KK, Feng J, Wang Y, Luo W, and Liang G
- Subjects
- Animals, Apoptosis drug effects, Cholesterol blood, Chronic Disease, Cytokines metabolism, Diet, High-Fat, Kidney Glomerulus drug effects, MAP Kinase Signaling System drug effects, Male, Mice, Mice, Inbred C57BL, NF-kappa B drug effects, Triglycerides blood, Anti-Inflammatory Agents therapeutic use, Curcumin analogs & derivatives, Curcumin therapeutic use, Kidney Diseases drug therapy, Kidney Diseases etiology, Obesity complications
- Abstract
Obesity has been recognized as a major risk factor for the development of chronic kidney disease, which is accompanied by increased renal inflammation, fibrosis, and apoptosis. C66 is a curcumin derivative that exerts anti-inflammatory effects by inhibiting the JNK pathway and prevents diabetic nephropathy. The present study investigates the possible protective effect of C66 on high-fat diet (HFD)-induced obesity-related glomerulopathy. Mice were fed with HFD for 8 weeks while some were treated with C66 every 2 days for 11 weeks. The HFD-fed mice developed renal dysfunction, as well as elevated triglyceride and cholesterol. Kidneys of the HFD-fed mice showed marked glomerular injuries, apoptosis, and inflammation with markedly increased cytokine production. Interestingly, treating HFD-fed mice with C66 remarkably reversed these pathological changes via inhibiting inflammation and NF-κB/JNK activation. In cultured mesangial cells, Palmitic Acid was able to activate the pro-fibrotic mechanisms, apoptosis, inflammatory response, and NF-κB and JNK signaling pathways, all of which could be attenuated by C66 treatment. In all, we demonstrated that curcumin analogue C66 attenuates obesity-induced renal injury by inhibiting chronic inflammation and apoptosis via targeting NF-κB and JNK. Our data suggest that C66 can be potentially used to prevent obesity-associated renal diseases warranting future investigations., (Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF